ICPerMed Conference 2018

Angel Alonso
Navarrabiomed, Spain
www.navarrabiomed.es

Lecture: Day 2, 10:35 – 11:20, ICPerMed Best Practice Award

After his medical degree, Angel Alonso was trained as a clinical geneticist and researcher in human genetics, serving in several senior clinical positions and research group leaderships for the last 20 years in Spain and the UK. Alonso paid a special attention to cancer genetics which became the greatest part of his scientific interest for a good number of years. In 2016, after holding a position at North East & North Cumbria NHS Genomic Medicine Centre, he started planning the design of the NAGEN 1000 project. Since then, Alonso felt strongly committed to the implementation of genomic medicine for the development of personalised medicine in public health services, and he has been very actively involved in numerous development strategic actions, being advisor of the Spanish Senate Commission for Genomic and Personalised Medicine and Secretary of Personalised Medicine Commission of the Spanish Society of Human Genetics AEGH.

Rafael de Andrés Medina
The National Institute of Health Carlos III (ISCIII), Spain
www.eng.isciii.es

Lecture: Day 1, 16:30 – 16:50, Public-public Partnerships for Research in Personalised Medicine, ERA-PerMed

Rafael de Andrés Medina is Chief Officer at the EU and Internationalization Department (Office of the Deputy Director General for International Research Programmes and Institutional Relations at the National Institute of Health Carlos III (ISCIII) in Spain. Rafael is also ICPerMed delegate and ESFRI Health and Food Strategic Working Group member. He is appointed as Chair of the ECRIN-ERIC Assembly of Members, the Spanish representative for other ESFRI landmarks (EATRIS-ERIC, EU-Openscreen-ERIC and ELIXIR), EJPs, JPIs (JPND, JPI HDHL, JPI MYBL, JPI AMR) and the president of the TFEU article 185 AAL (two terms: September 2013 – April 2018).

His portfolio encompasses planning and translational research. His interest ranges from 4P Health (predictive, preventive, personalized, participate), social inclusiveness, demographic change and ageing to Research and Innovation policy.

Miguel Antunes
National Authority of Medicines and Health Products (INFARMED), Portugal
www.infarmed.pt

Lecture: Day 1, 16:50 – 17:10, 2nd Best Practice Example of Personalised Medicine Policy: Personalised Approaches of the Portuguese Adverse Drug Reaction

Graduated in Pharmaceutical Sciences and Master in Public Health, he holds post-graduation Diplomas in Public Management, Pharmaceutical Medicine, Bioethics and Genetics.

He has been working for the Portuguese National Authority of Medicines and Health Products – INFARMED since 1998, currently as a pharmacovigilance manager/assessor. He was formerly director of the medical devices vigilance Unit and of the Notified Body Unit and adviser to the Management Board.

He was a member in several expert groups on medical devices from the European Commission and has been an invited speaker in several national and international events, mostly in medical devices regulation and in socio-economical assessment of medical technology.

Fabian Bolin
WarOnCancer, Sweden
www.waroncancer.com

Lecture: Day 1, 14:00 – 15:10, 2nd Best Practice Example of Personalised Medicine Research & Implementation – From Basic Research to the Patient: Genomic Medicine Sweden (GMS) – Acceleration of Implementation of Personalised Medicine for Rare Diseases and Cancer

Fabian Bolin is the CEO & co-founder of WarOnCancer, a digital health company on a mission to radically improve mental health for people affected by cancer. The company is currently developing the WarOnCancer App – a storytelling platform for patients, survivors and loved ones.

Fabian studied business at Stockholm School of Economics followed by work in investment banking. He has also worked in the film industry as an actor.

After being diagnosed with leukemia, Fabian began documenting his cancer battle on a blog, which quickly gained global attention. He won the award “Journalist of the Year 2015” and recently ranked No. 1 as most influential in the Swedish MedTech industry 2018.

Mafalda Bourbon
National Health Institute Doutor Ricardo Jorge (INSA), Portugal
www.insa.pt

Lecture: Day 2, 11:50 – 13:00, 3rd Best Practice Example of Personalised Medicine Research & Implementation – From Basic Research to the Patient: Translational medicine in familial Hypercholesterolaemia – from Phenotype to Genotype to Treatment

Mafalda Bourbon has a PhD in Clinical Sciences by the Imperial College Faculty of Medicine, London, UK. She is founder and coordinator of the Portuguese Familial Hypercholesterolaemia (FH) Study since 1999 and coordinator of the Research and Development Unit, Department of Health Promotion and Prevention of Noncommunicable Diseases at the National Institute of Health Doutor Ricardo Jorge (INSA), Lisbon, Portugal. She is also Head of the Cardiovascular Research Group at INSA and integrated member of the Biosystems & Integrative Sciences Institute (BioISI).

Mafalda is invited Professor at Faculty of Sciences of the University of Lisbon, Lisbon, Portugal and member of the board of the Iberoamerican FH Network and National Lead Investigator for the 2 FH registries: FHSC and International Paediatric FH Registry. She is also chair of the FH Expert Panel Variant Curation at Clinical Genome Resource (ClinGen Cardiovascular).

Wolfgang Burtscher
Deputy Director-General – Directorate “Research and Innovation” (RTD), European Commission
ec.europa.eu

Lecture: Day 1, 10:10 – 10:40, Opening Statement

Reinhard Büttner
University Hospital Cologne, Germany
www.uk-koeln.de

Lecture: Day 1, 11:30 – 12:40, 1st Best Practice Example of Personalised Medicine Research & Implementation – From Basic Research to the Patient: The Network Genomic Medicine in Germany – Implementing Personalised Lung Cancer Care in Clinical Routine

Reinhard Büttner is Professor and Chairman of The Institute of Pathology at University Hospital Cologne, Köln, Germany, and the Co-Founder and Chief Scientific Officer of TARGOS Molecular Diagnostics. He completed his medical degree at the University of Mainz, Mainz, Germany, in 1985, before starting a residency at Rheinisch-Westfalische Technische Hochschule RWTH Aachen, Aachen, Germany. In 1987, he began post-doctoral work at the Gene Centre Munich and MD Anderson Cancer Centre, Houston, TX, USA (1987‒1990). Returning to Germany in 1991, he took up a residency at the University of Regensburg, before becoming Professor and Chairman for Pathology at RWTH Aachen (1999‒2001). After which, he worked as a Professor and Chairman of Pathology at the University of Bonn (2001‒2011), before being appointed to his current position as Professor and Chairman of Pathology at the University of Cologne in 2011.

Reinhard Büttner specialises in molecular pathology and is a member of a number of academic societies including the German Society of Pathology and the International Academy of Pathology. He is the Co-President of the International Academy of Pathology World Congress of Pathology, Cologne 2016. He has more than 450 peer-reviewed papers published in high-impact internationally renowned journals.

Cristian Busoi
Member of the European Parliament
www.europarl.europa.eu

Lecture: Day 1, 10:10 – 10:40, Opening Statement

Monika Frenzel
ICPerMed Secretariat, French National Research Agency (ANR), France
www.agence-nationale-recherche.fr

Lecture: Day 1, 13:40 – 14:00, ICPerMed Survey and Database

Dr. Monika Frenzel, Senior Scientific Officer for transnational collaborations in the Biology and Health department of The French National Funding Agency (L’Agence Nationale de la Recherche), represents ANR in several transnational collaborations and international funding programmes. As such, she is part of the coordination and support action (CSA) ICPerMed Secretariat and ICPerMed itself. She represents ANR within the ERA Net on Personalised Medicine ERA PerMed and was appointed chair for the respective programme.

Monika Frenzel completed her PhD in Physical Biochemistry and Radiation Biology and worked as researcher in the field of cytogenetics and cohort studies.

Gaetano Guglielmi
ICPerMed Member, Italian Ministry of Health, Italy
www.salute.gov.it

Lecture: Day 2, 10:35 – 11:20, ICPerMed Best Practice Award

Gaetano Guglielmi MD PhD, is the Head of the Office of Health Research, DG for Research and Innovation in Healthcare. Since 2009 he is national representative in several international and European research programs such as ERA-NET NEURON, JPco-fuND, EuroNanoMed, E-Rare, ERA PerMed, EraCoSymed, JPIAMR, ERA-CVD, Infect-ERA and JPI MYBL, AAL and deputy coordinator in TRANSCAN and TRANSCAN-2. Guglielmi is responsible for the verification of research activities IRCCS and related management of funds.

Thorsten Gutjahr
AstraZeneca, United Kingdom
www.astrazeneca.co.uk

Lecture: Day 2, 09:45 – 10:15, Keynote 3: Precision Medicine: From patient need to providing solutions in clinical practise

Thorsten Gutjahr is a distinguished scientist and leader in Precision Medicine, Biomarkers and Companion Diagnostics. He develops precision medicine solutions with a focus on Oncology. Since 2014, Thorsten has held the position of Global Head of Companion Diagnostics at AstraZeneca, within the Precision Medicine and Genomics function. He leads an Oncology CDx team that has delivered 19 new Diagnostic tests, including diagnostics for Olaparib, Osimertinib, Durvalumab and Gefitinib. Thorsten plays a leadership role in the development of AstraZeneca’s Precision Medicine strategy, with Diagnostic development of multigene panels and novel ctDNA approaches a key focus.

Before joining AstraZeneca, Thorsten was at Roche for >12 years, both in the Pharmaceuticals and the Diagnostics Division. He led the personalised healthcare teams for Trastuzumab and Erlotinib, and delivered >30 biomarkers for Diagnostics. Thorsten studied at the Universities of Stuttgart-Hohenheim & Tubingen (Germany), and the University of Sussex (UK). He gained his PhD in molecular biology at the University of Stuttgart, and completed a post-doc at the Hematology/Oncology School of Medicine, University of California in San Diego.

Marian Harkin
Member of the European Parliament
www.europarl.europa.eu

Lecture: Day 1, 10:10 – 10:40, Opening Statement

Gabriele Hanauer-Mader
FH Austria, Austria

Lecture: Day 2, 11:50 – 13:00, 3rd Best Practice Example of Personalised Medicine Research & Implementation – From Basic Research to the Patient: Translational medicine in familial Hypercholesterolaemia – from Phenotype to Genotype to Treatment

Born in Vienna, Austria, Gabriele Hanauer-Mader is an English/Spanish major and worked as a journalist, copywriter, and public relations expert before her daughter was born in 2000. When her daughter was diagnosed with a severe form of familial hypercholesterolemia at the age of 3, Gabriele founded an FH patient support group that later became FHchol Austria, an FH patient organization & charity. As president, it is her goal to raise awareness of this genetic but easily manageable lipid disorder to prevent patients from suffering cardiovascular disease. She also works as coordinator for an FH registry project in Austria.

Sebastian Hermelin
WarOnCancer, Sweden
www.waroncancer.com

Lecture: Day 1, 14:00 – 15:10, 2nd Best Practice Example of Personalised Medicine Research & Implementation – From Basic Research to the Patient: Genomic Medicine Sweden (GMS) – Acceleration of Implementation of Personalised Medicine for Rare Diseases and Cancer

Sebastian Hermelin is COO and Co-Founder of WarOnCancer, a digital health company on a mission to radically improve mental health for people affected by cancer. Sebastian is leading WarOnCancer’s co-creation projects together with the biopharmaceutical- and healthcare industry. Amongst them the project ”Blockchain to Empower Patients” which aims to better understand the potential in patient-reported data and how this data can be collected in a continuous and sustainable way.

The company is currently developing the WarOnCancer App – a storytelling platform for patients, survivors and loved ones.

Sebastian has experience of work related to consumer retail, media and the financial sector. He holds a M.Sc in industrial Engineering, specializing in Energy Systems from the Royal Institute of Technology (KTH), Sweden.

Steve Humphries
Store Gene, United Kingdom
www.storegene.com

Lecture: Day 2, 11:50 – 13:00, 3rd Best Practice Example of Personalised Medicine Research & Implementation – From Basic Research to the Patient: Translational medicine in familial Hypercholesterolaemia – from Phenotype to Genotype to Treatment

Steve Humphries is a world-renowned expert in cardiovascular genetics, a field in which he has worked for over 30 years. He worked at University College London from 1991, where he was the British Heart Foundation Professor of Cardiovascular Genetics. He retired in September 2015 and is the UCL Emeritus Professor of Cardiovascular Genetics. Professor Humphries has an h index of >100 and has published over 700 papers and more than 230 review articles and has supervised 39 PhD and 8 MD thesis students. From 2008-2015 he was the Editor in Chief of the international journal Atherosclerosis.

He has directed a major research programme to develop and implement molecular strategies to study the causes and clinical and psychological consequences of Familial Hypercholesterolaemia (FH). He was the Lead Advisor to the UK NICE guidelines on FH published in 2008, and for the NICE 2017 update of these guidelines. He directed the 2010 UK audit of FH services and has set up an FH Pediatric Register under the auspices of the RCP and RCPCH. He has published on the health economics of cascade testing for FH, and is the Director of the international FH mutation database. He is actively involved with teaching, ethics, and public awareness aspects of the development of genetic testing for complex late-onset disorders.

Jan-Ingvar Jönsson
Swedish Research Council
www.vr.se

Lecture: Day 1, 14:00 – 15:10, 2nd Best Practice Example of Personalised Medicine Research & Implementation – From Basic Research to the Patient: Genomic Medicine Sweden (GMS) – Acceleration of Implementation of Personalised Medicine for Rare Diseases and Cancer

Jan-Ingvar Jönsson is currently Secretary General for Medicine and Health at the Swedish Research Council, where he has held several commissions since 2013. His main responsibilities are the development of high quality research programs and funding schemes in medicine, life science and clinical research as well as in public health and health care research. He is also involved in different aspects of assessment and impact of research within the health care sector.

Jan-Ingvar has a background in immunology and obtained his PhD after five years at the Max-Planck-Institute in Freiburg, Germany. After working as postdoctoral researcher in stem cell biology at the Hospital for Sick Children in Toronto, Canada, he returned to Sweden in the mid 90’s to establish a career as independent investigator in haematology cancer biology, and drug targeting.

He is national representative of several international organisations and is since 2016 vice-chair of Joint programming initiative of antimicrobial resistance (JPIAMR). In addition, he is involved in collaboration between several other research funding agencies and policy makers worldwide. For example, he is chair of the joint committee of the Nordic medical research councils, board member of JPND in neurodegenerative diseases, and member of the Governing Council of WHO international agency for research on cancer (IARC).

Walter Kolch
Systems Biology Ireland
www.ucd.ie/sbi

Lecture: Day 2, 10:15 – 10:35, 3rd Best Practice Example of Personalised Medicine Policy: TOPMed10 – Training the Next Generation of Leaders in Personalised Medicine.

Walter Kolch is Director of Systems Biology Ireland and the Conway Institute at University College Dublin (Ireland). He is best known for his work in oncogene signal transduction, proteomics and systems biology. Having obtained a MD from the University of Vienna, Austria, Walter worked in academia, research institutions and pharmaceutical industry in the USA, Germany, Great Britain and Ireland. His current research interest focuses on understanding how biochemical networks specify biological decisions, and how systems biology approaches can help clinical advances in personalised medicine.

Anna Kron
University Hospital Cologne, Germany
www.ngm-cancer.com

Lecture: Day 1, 11:30 – 12:40, 1st Best Practice Example of Personalised Medicine Research & Implementation – From Basic Research to the Patient: The Network Genomic Medicine in Germany – Implementing Personalised Lung Cancer Care in Clinical Routine

Anna Kron ist the Head of Business Unit of the national Network Genomic Medicine Lung Cancer at the University Hospital Cologne in Germany. The network strives to offer comprehensive and high-quality molecular diagnostics for all patients with lung cancer and thus to promote the implementation of personalised therapy in routine clinical care. Anna has a background in health economics and specialized in clinical trials and evidence based medicine. Before coming to the national Network Genomic Medicine Lung Cancer, Anna served as the Head of Financial Management and Controlling at the ClinicalTrial Unit at the University Hospital Cologne.

João Lavinha
National Health Institute Doutor Ricardo Jorge (INSA), Portugal
www.insa.pt

Lecture: Day 2, 11:50 – 13:00, 3rd Best Practice Example of Personalised Medicine Research & Implementation – From Basic Research to the Patient: Translational medicine in familial Hypercholesterolaemia – from Phenotype to Genotype to Treatment

João Lavinha is Head of the Research & Development Unit, Human Genetics Department, National Institute of Health Ricardo Jorge (INSA), Lisboa, Portugal. He has held other positions at INSA over the years including Director-general (2000-2004). He received his equivalent to PhD from INSA (1994) and his MSc (Medical Science) from the University of Glasgow (1983), having previously graduated (BSc) in Pharmacy and Chemistry from the University of Lisboa (1969, 1977). He is (co)-author of 103 papers, 76 of which in international peer-reviewed journals. His current research interests include molecular etio-pathogenesis and epidemiology of genetic disease, public health genomics and genetics of the response to environmental stressors in human-relevant models. Since 2016 he is a member of the Portuguese Clinical Research Ethics Review Board. He has been elected to the board of the European Society of Human Genetics (1997-2002).

Catalina Lopez-Correa
Genome British Columbia, Canada
www.genomebc.ca

Lecture: Day 1, 15:40 – 16:00, 1st Best Practice Example of Personalised Medicine Policy: The Canadian Path from Discovery to Implementation of Personalised Medicine Approaches

Dr. Catalina Lopez-Correa is Genome BC’s Chief Scientific Officer and VP Sectors. Her deep understanding of genomics has inspired leaders in science and industry to collaborate towards solving some of the world’s greatest challenges. Dr. Lopez-Correa holds a Medical degree from the UPB in Colombia, a Master’s degree in Human Genetics from Paris V University in France, a PhD in Medical Sciences and Genetics from the KULeuven in Belgium, and a mini MBA from McGill University in Canada. Dr. Lopez-Correa has held leadership positions at Informax, deCODE Genetics, Eli Lilly and Genome Quebec and has played advisory roles at the European Commission, Innovative Medicine Initiatives and other private and public sector entities working in the application and implementation of genomics technologies.

Marco Marsella
Directorate General for Communications Networks, Content and Technology
ec.europa.eu

Lecture: Day 1, 10:10 – 10:40, Opening Statement

Consuelo Martin de Dios
Fundación Instituto Roche, Spain
www.institutoroche.es

Lecture: Day 2, 10:35 – 11:20, ICPerMed Best Practice Award

Bachelor of Science specializing in Fundamental Biology by the Complutense University of Madrid (Spain). She has taken Doctorate courses in Genetic Engineering, Metabolism and Biotoxicology.

She has also completed postgraduate studies in Marketing, Financial Foundations for Management and Lobby and Public Affairs among others.

With more than 30 years of experience in the Pharmaceutical Industry in several laboratories where she has held different positions in different Departments: Medical, Marketing and Patient Access. At present, since February 2016 she is Managing Director of Roche Institute Foundation (Foundation that Roche Farma has set up in 2004 in Spain).

© Bundesregierung/Guido Bergmann

Veronika von Messling
Director General Life Sciences, Federal Ministry of Education and Research (BMBF), Germany
www.bmbf.de

Lecture: Day 1, 09:30 – 10:10, Welcome and Introduction

Prof. Dr. Veronika von Messling, is Director General of the Life Science Division at the German Federal Ministry of Education and Research. She obtained her veterinary degree and her doctorate degree in veterinary virology from the Veterinary School Hannover, Germany. After postdoctoral training at Mayo Clinic in Rochester, MN, she was Assistant Professor at INRS-Institut Armand-Frappier in Laval, QC, and then Associate Professor at Duke-NUS Medical School, Singapore, before becoming Director of the Veterinary Division at Paul-Ehrlich-Institute, the German Federal Institute of Vaccines and Biomedicines, in Langen, Germany. Her expertise lies in the development of novel prophylactic and therapeutic strategies against infectious diseases.

Sebastian Michels
University Hospital Cologne, Germany
www.uk-koeln.de

Lecture: Day 1, 11:30 – 12:40, 1st Best Practice Example of Personalised Medicine Research & Implementation – From Basic Research to the Patient: The Network Genomic Medicine in Germany – Implementing Personalised Lung Cancer Care in Clinical Routine

Sebastian Michels is subinvestigator at the Lung Cancer Group Cologne (Germany) and resident in medical oncology and hematology at the University of Cologne. Michels is medical coordinator of EATON, a phase I trial with EGF816 and Trametinib in EGFR T790M-positive NSCLC, and EUCROSS, a phase II trial to evaluate efficacy and safety of crizotinib in advanced adenocarcinoma oft he lung harbouring ROS1 translocations.

Jenni Nordborg
National coordinator Office for Life Science, Sweden
www.lifesciencesweden.se

Lecture: Day 1, 14:00 – 15:10, 2nd Best Practice Example of Personalised Medicine Research & Implementation – From Basic Research to the Patient: Genomic Medicine Sweden (GMS) – Acceleration of Implementation of Personalised Medicine for Rare Diseases and Cancer

Jenni Nordborg, PhD, is National Coordinator and Director of Life Sciences at the Government Offices of Sweden, heading the Office for Life Sciences. The Office for Life Sciences coordinates policy between the Ministry of Social Affairs, the Ministry of Research and Higher Education, the Ministry of Enterprise and Innovation, and is responsible for forming a new Swedish Life Science Strategy. Dr. Nordborg is also Director and Head of the Health Division at Vinnova, the Swedish Governmental Innovation Agency. She is active in strategic innovation policy development and implementation within health and life science on national and international level. Her network includes international innovation policy, entrepreneurship and the health and life science ecosystem.

Dr. Nordborg has a research background from Chalmers University of Technology, and experience from senior management positions in both the private and public sector. She has an entrepreneurial background from commercialization of research, and international marketing and sales experience. Together with the founding team she built up the laser company Cobolt AB to an international position. She also has experience in board level positions both in private companies and governmental organizations.

Mairéad O’Driscoll
ICPerMed Chair
Health Research Board (HRB), Ireland
www.hrb.ie

Lecture: Day 1, 10:40 – 11:00, Introduction to ICPerMed

Mairéad O’Driscoll is the Director of Research Strategy and Funding at the Health Research Board (HRB), the lead funding agency in Ireland for health and social care research. She has been Chair of the Executive Committee of ICPerMed since 2016.

Before being appointed Director of Funding, she was Head of Policy, Evaluation and External Relations at the HRB. She worked as a researcher in academia and the biotechnology industry before moving into policy research, first with the Royal Society in London and then with the Wellcome Trust. She also spent time in South Africa where she worked on the development of a national research and technology foresight study. She is a member of several national and international groups and is a graduate of Trinity College, Dublin, and the University of London.

Katherine Payne
University of Manchester, United Kingdom
www.manchester.ac.uk

Lecture: Day 1, 11:00 – 11:30, Keynote 1: Personalised Medicine and Health Economics – The Art of Defining Benefit for Individuals and Society

Katherine Payne was awarded a personal chair in health economics at The University of Manchester in August 2010. Katherine is also a registered pharmacist and was awarded the status of Fellow of the Royal Pharmaceutical Society in 2016. She is now based within the Manchester Centre for Health Economics at The University of Manchester. Katherine’s research interests focus on the economics of precision medicine including the evaluation and valuation of genomic technologies and services. Katherine has an interest in the use of economic evidence to inform decision-making in practice and was a member of a NICE Technology Appraisal Committee between October 2003 and 2012. Katherine has been a member of national funding review panels for large scale programmes and projects on the economics of precision medicine for Canada, UK, The Netherlands, France and Luxembourg.

Daryl Pritchard
Personalized Medicine Coalition, USA
www.personalizedmedicinecoalition.org

Lecture: Day 1, 16:00 – 16:30, Keynote 2: Clinical Implementation – Challenges and Solution Strategies

Daryl Pritchard, Ph.D., is the Senior Vice President of Science Policy at the Personalized Medicine Coalition (PMC), where he leads PMC’s efforts to increase awareness and understanding of personalized medicine; identify and address barriers to the adoption of personalized medicine into the health care system; and develop and promote appropriate clinical, health care infrastructure, regulatory, and payment policies that will help advance patient-centered, personalized health care.

Before coming to PMC, Dr. Pritchard served as the Director of Policy Research at the National Pharmaceutical Council (NPC). Prior to joining NPC, he served as the Director of Research Programs Advocacy and Personalized Medicine at the Biotechnology Industry Organization (BIO).

Dr. Pritchard received his Ph.D. and master’s degree in genetics from the George Washington University, and completed a post-doctoral research fellowship at the Children’s National Medical Center. He was awarded the first American Society of Human Genetics (ASHG)/National Human Genome Research Institute (NHGRI) Fellowship in Genetics and Public Policy, where he worked as a health legislative assistant in the House of Representatives.

Joachim Reischl
AstraZeneca, Sweden
www.astrazeneca.com

Lecture: Day 1, 14:00 – 15:10, 2nd Best Practice Example of Personalised Medicine Research & Implementation – From Basic Research to the Patient: Genomic Medicine Sweden (GMS) – Acceleration of Implementation of Personalised Medicine for Rare Diseases and Cancer

Joachim Reischl joined AstraZeneca in 2015 as VP, Head of Precision Medicine Policy, Portfolio and Externalisation. In this role, Joachim is the Precision Medicine and Genomics site head in Gothenburg and a member of the global AstraZeneca Precision Medicine and Genomics leadership team responsible for diagnostic alliances and business excellence. Joachim has over 15 years pharmaceutical R&D experience. Before joining AstraZeneca, Joachim headed the Global Biomarker Strategy and Development function at Bayer. Joachim is passionate to drive transformational change in pharma to maximize innovation and productivity for the benefits of patients. He has a strong interest in next generation technologies and their application to precision medicine.

Étienne Richer
McGill University and Canadian Institutes of Health Research (CIHR), Canada
www.mcgill.ca
www.canada.ca

Lecture: Day 1, 15:40-16:00, 1st Best Practice Example of Personalised Medicine Policy: The Canadian Path from Discovery to Implementation of Personalised Medicine Approaches

Dr. Étienne Richer first joined McGill University as a postdoctoral scientist in genetics of infectious diseases. Dr. Richer then joined BioMedCom Consultants where he was involved in projects covering a broad range of healthcare issues from biologics therapies to reimbursement policies. Dr. Richer returned to McGill in 2011 as the Associate Director for the CIHR Institute of Genetics. Dr. Richer has been involved in the strategic orientation of the institute, the development of its team and the delivery of its activities. While establishing tight links with the national research community, an international focus is also infused in these three sectors. Personalized medicine and rare diseases constitute two area of focus of his work as he has been involved since 2012 in CIHR’s Personalized Medicine Initiative and Personalized Health Initiative, was a member of the CSA PerMed, is member of IC PerMed and E-Rare and is involved in the development of ERA PerMed.

Richard Rosenquist
Karolinska University Hospital, Sweden
www.karolinska.se

Lecture: Day 1, 14:00 – 15:10, 2nd Best Practice Example of Personalised Medicine Research & Implementation – From Basic Research to the Patient: Genomic Medicine Sweden (GMS) – Acceleration of Implementation of Personalised Medicine for Rare Diseases and Cancer

Richard Rosenquist Brandell is Professor of Clinical Genetics at Karolinska Institutet and Senior Physician in Clinical Genetics at Karolinska University Hospital, Sweden. He received his medical degree and PhD degree at Umeå University, Sweden, and undertook a postdoctoral period at the Department of Pathology, Frankfurt am Main, Germany. He became Professor of Molecular Hematology in 2007 at Uppsala University. He has initiated and led the SciLifeLab Clinical Genomics Facility in Uppsala between 2013-2017 and is currently Platform Director for the national Diagnostics Development Platform within SciLifeLab. More recently, he is coordinating the Genomics Medicine Sweden initiative that aims to build a new type of infrastructure within Swedish healthcare that implements precision medicine at a national level.

Achim Rothe
Medical Oncologist, Germany

Lecture: Day 1, 11:30 – 12:40, 1st Best Practice Example of Personalised Medicine Research & Implementation – From Basic Research to the Patient: The Network Genomic Medicine in Germany – Implementing Personalised Lung Cancer Care in Clinical Routine

Gerhard Schillinger
AOK Bundesverband, Germany
www.aok-bv.de

Lecture: Day 1, 11:30 – 12:40, 1st Best Practice Example of Personalised Medicine Research & Implementation – From Basic Research to the Patient: The Network Genomic Medicine in Germany – Implementing Personalised Lung Cancer Care in Clinical Routine

Eric Sijbrands
Erasmus Medical Centre, Netherlands
www.erasmusmc.nl

Lecture: Day 2, 11:50 – 13:00, 3rd Best Practice Example of Personalised Medicine Research & Implementation – From Basic Research to the Patient: Translational medicine in familial Hypercholesterolaemia – from Phenotype to Genotype to Treatment

Prof. Dr. Eric Sijbrands is one of the founding fathers of the Dutch national molecular diagnostics program for familial hypercholesterolemia and he tested the clinical value of this worldwide first and largest population-based genetic diagnostic screening program. His work improved the insurability of patients with familial hypercholesterolemia: identified and on statins they now pay regular premiums. He is specialized in collecting databases and biobanks of deep phenotyped cohorts with the specific properties that enhance translational research. His research group is active in the fields of genetic epidemiology of cardiovascular disease, hyperlipidaemia, hypertension, and diabetes mellitus.

Bärbel Söhlke
Patient, Germany

Lecture: Day 1, 11:30 – 12:40, 1st Best Practice Example of Personalised Medicine Research & Implementation – From Basic Research to the Patient: The Network Genomic Medicine in Germany – Implementing Personalised Lung Cancer Care in Clinical Routine

Bärbel Söhlke is a mathematician and has worked in corporate finance, business controlling and system development in the chemical industry. She was diagnosed with advanced lung cancer at the age of 50. She experienced various treatments and repeated relapses until comprehensive molecular diagnostics were performed by the lung cancer group Cologne. Her tumor was found to harbor the rare ROS1 translocation. Subsequent targeted therapy resulted in significant clinical improvements and a complete tumor remission for six years to date. Bärbel is engaged in a global group of more than 300 patients and caregivers in 30 countries dealing with ROS1-positive cancer that strives to increase awareness and education, accelerate research, and improve access to effective diagnosis and treatment.

Roman Thomas
University Hospital Cologne, Germany
www.uk-koeln.de

Lecture: Day 1, 11:30 – 12:40, 1st Best Practice Example of Personalised Medicine Research & Implementation – From Basic Research to the Patient: The Network Genomic Medicine in Germany – Implementing Personalised Lung Cancer Care in Clinical Routine

Daniel Todt
Ruhr-University Bochum, Germany
www.ruhr-uni-bochum.de

Lecture: Day 2, 10:35 – 11:20, ICPerMed Best Practice Award

Daniel Todt is a bioinformatician in virology research at the Ruhr University in Bochum, Department of Molecular and Medical Virology. After his studies in bioinformatics and biomedicine, he did his PhD in 2017 at Twincore – Institute for Experimental and Clinical Infection Research in Hannover. His special concern lays in the emergence of drug resistance mutations in the genomes of RNA viruses, particularly hepatitis virus. The rapid translation of findings into clinical applications in personalised infection medicine is of particular interest to him.

Anna Wedell
Karolinska University Hospital, Sweden
www.karolinska.se

Lecture: Day 1, 14:00 – 15:10, 2nd Best Practice Example of Personalised Medicine Research & Implementation – From Basic Research to the Patient: Genomic Medicine Sweden (GMS) – Acceleration of Implementation of Personalised Medicine for Rare Diseases and Cancer

Anna Wedell, MD, PhD, is a Clinical Geneticist and Professor of Medical Genetics at the Department of Molecular Medicine & Surgery, Karolinska Institutet, and Head of the Centre for Inherited Metabolic Diseases (CMMS), Karolinska University Hospital. During 2010 – 2013, she was Clinical Director at SciLifeLab in Stockholm, developing clinical whole genome sequencing for diagnosis of rare diseases which has subsequently been implemented at the Karolinska University Hospital. Anna Wedell is Chairman of the Medical Nobel Committee, member of the Royal Swedish Academy of Sciences, and member of the Royal Swedish Academy of Engineering Sciences.

© BMG

Sabine Weiss
Parliamentary State Secretary to the German Federal Minister of Health
www.bmg.de

Lecture: Day 1, 09:30 – 10:10, Welcome and Introduction

Jürgen Wolf
University Hospital Cologne, Germany
www.uk-koeln.de

Lecture: Day 1, 11:30 – 12:40, 1st Best Practice Example of Personalised Medicine Research & Implementation – From Basic Research to the Patient: The Network Genomic Medicine in Germany – Implementing Personalised Lung Cancer Care in Clinical Routine

Jürgen Wolf, MD, is currently Medical Director of the Center for Integrated Oncology (CIO) at the University Hospital Cologne. He holds a professorship for Interdisciplinary Translational Oncology at the University of Cologne and is speaker of the CIO lung cancer program.

Prof. Wolf received his MD degree from the University of Freiburg. He spent his postdoctoral fellowship at the German Cancer Research Center Heidelberg (1986-1990). In 1990 he started his clinical training in the Department of Internal Medicine, University Hospital of Cologne. He headed the Laboratory for Research on Hodgkin´s Lymphoma in Cologne (1990-2003) and was co-chairman of the German Hodgkin´s Lymphoma Study Group (2000-2004). From 2004 he coordinated the establishment of the Center for Integrated Oncology (CIO) at the University Hospital of Cologne. In 2005 he initiated the lung cancer program in the CIO and founded the Lung Cancer Group Cologne. In 2010 he co-founded the Network Genomic Medicine (NGM) Lung Cancer, a health care provider network integrating now more than 250 centers in Germany for centralized next-generation-sequencing based molecular genotyping and allocation of patients to personalized treatment in and outside clinical trials. For foundation of the Network Genomic Medicine he received the Innovation Award of the state of North Rhine-Westphalia in 2016 and has been Speaker of the national Netword Genomic (nNGM) Lung Cancer funded by the German Cancer Aid since 2018.

Cong Yu
BGI Group, China
www.bgi.com

Lecture: Day 2, 13:00 – 13:30, Keynote 4: International views of Personalised Medicine – The Chinese perspective

Dr. Yu is the Executive Vice President of BGI Genomics, which is a global leading genomics organization. In that role, he is in charge of the company’s global development, operation, and M&A. Meanwhile, Dr. Yu is the General Manager of BGI group in Sichuan Province, China. With more than 8 years experience in the genomics and diagnostics industry, he leads BGI community to promote precision medicine application in China and in Europe. Prior to taking over the Executive Vice President role, Dr. Yu serves as the COO of BGI Europe and Vice president of BGI Europe.